hsa-mir-3170: Hsa-mir-3170 is a down-regulated miRNA that has been identified as a potential prognostic indicator in various types of cancer, including sarcoma, endometrial cancer, and breast cancer [PMC8806668] [PMC8797695] [PMC4289319]. In sarcoma, hsa-mir-3170 is one of the miRNAs included in a risk score formula that predicts the risk of the disease [PMC8806668]. It is down-regulated in sarcoma tissue samples and has been found to target genes such as MEF2D, RAB5C, CDKN1A, DNASE2, APOL6, RAB13, HACD4, and POLL [PMC8797695]. In endometrial cancer (EC), hsa-mir-3170 is associated with overall survival (OS), with high expression being linked to increased survival rates [PMC9713471]. Additionally, hsa-mir-3170 has been found to be low-expressed in EC tissues and its low expression can lead to translational inhibition or instability of target mRNA [PMC9318842]. In breast cancer, hsa-mir-3170 has been detected in tumor tissue compared to normal breast tissue samples [PMC4289319]. Furthermore, hsa-mir-3170 has also been identified as being associated with genetic variations in genes such as IL1B and FCGR3A [PMC7456829]. Overall, hsa-mir-3170 plays an important role in cancer prognosis and may have potential clinical implications for the management of various types of cancer. However further experimental validation is needed to confirm its role.